Cancer vaccine (Tohoku University)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCancer vaccine (Tohoku University)

Drug Alias Namecancer/testis antigen/VEGFR1/2 peptide vaccine

ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine

Mechanisms of ActionVascular endothelial growth factor receptor 2 modulatorsVascular endothelial growth factor receptor 1 modulators

TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 2

Therapy Area/IndicationsNeoplasm MetastasisGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTohoku University

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesTohoku University

Active IndicationsN/A

Inactive IndicationsNeoplasm MetastasisGastrointestinal Neoplasms

ATC CodeN/A